Drug intelligence / Profile preview

ES302

Development stage: Preclinical
Lead developer: Elpiscience
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

ES302 is a preclinical-stage bispecific antibody developed by Elpiscience for the treatment of inflammatory bowel disease (IBD). It simultaneously targets tumor necrosis factor-like ligand 1A (TL1A) and the p19 subunit of interleukin-23 (IL-23p19). By blocking these two distinct inflammatory pathways, ES302 aims to provide enhanced therapeutic efficacy compared to monotherapies targeting either pathway alone. TL1A is involved in mucosal inflammation and fibrosis, while IL-23 is a key driver of the Th17 response, both of which are central to the pathogenesis of Crohn's disease and ulcerative colitis.

Targets

IL23A (Interleukin-23 p19 Subunit)TL1A (TNF-like cytokine 1A)

Beyond the preview

Go deeper on ES302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ES302.

Explore the full profile